ArticleEuropean radiology experimental2026
AI-driven ablative margin assessment after HCC radiofrequency ablation: a case-control feasibility study.
Article in European radiology experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThermal ablation of hepatocellular carcinoma (HCC) requires an adequate safety margin around the tumor to ensure treatment success. In this retrospective study, we evaluated an artificial intelligence (AI) pipeline for automatic safety margin assessment on computed tomography (CT) scans, with the goal of supporting radiologists in taking immediate clinical actions. MATERIALS AND
methodsWe included CT scans from patients with primary liver cancer treated at the local university hospital with radiofrequency ablation (RFA) between 2010 and 2022. The study group consisted of 43 randomly picked lesions with local tumor progression, with an average diameter of 35 mm [24-45] (median [interquartile range]). For comparison, we randomly selected 96 lesions showing no local tumor progression via propensity matching (diameter 28 mm [17-37]). To calculate the minimum ablative margin (MAM), we coregistered the intraprocedural patient scans with a recently proposed AI-based image registration model.
resultsOverall, 139 HCC cases were evaluated, with an average follow-up interval of 25 months [8-42] (median, interquartile range). The calculated MAM was found to be a significant predictor of local tumor progression (odds ratio 0.42, 95% confidence interval 0.35-0.50, p = 0.001). Significant differences in local tumor protection rate were found between the lesions grouped by MAM (p < 0.001).
conclusionOur AI-driven pipeline enabled fast and reliable assessment of the efficacy of RFA of HCC in relation to ablative margins. RELEVANCE STATEMENT: The ablative margins have been automatically quantified using a novel method that combines AI-based segmentation with AI-driven image registration. By delivering robust margin quantification quickly, the proposed pipeline can help clinicians in assessing ablative margins intraoperatively. KEY POINTS: An AI-driven tool can rapidly and automatically measure the treatment margin after liver cancer ablation. Inadequate safety margins calculated with the proposed pipeline are associated with a higher risk of local tumor recurrence. A MAM of 2.50 mm suffices to lower the risk of local tumor progression to below 10%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.